홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /반응

Hydrochloric Acid → (R)-tert-butyl 1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-ylcarbamate

HRID 77310
인쇄

반응식

HRID 77310 반응식
[ClH:1].[ClH:2].N[C@@H]1CCN(C2C=C(NCCOC)N=NC=2)C1.COCCN[C:25]1[N:30]=[N:29][CH:28]=[C:27]([N:31]2[CH2:35][CH2:34][C@@H:33]([NH:36][C:37](=[O:43])[O:38][C:39]([CH3:42])([CH3:41])[CH3:40])[CH2:32]2)[CH:26]=1.Cl>CO.CCOCC>[Cl:1][C:26]1[C:27]([N:31]2[CH2:35][CH2:34][C@@H:33]([NH:36][C:37](=[O:43])[O:38][C:39]([CH3:42])([CH3:41])[CH3:40])[CH2:32]2)=[CH:28][N:29]=[N:30][C:25]=1[Cl:2]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 313Hydrochloric AcidHCID 67087365(R)-tert-butyl 1-(6-(2-methoxyethylamino)pyridazin-4-yl)pyrrolidin-3-ylcarbamateHCID 67087570(R)-5-(3-aminopyrrolidin-1-yl)-N-(2-methoxyethyl)pyridazin-3-amine dihydrochloride

생성물 1

HCID 86652500(R)-tert-butyl 1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-ylcarbamate수율 52%

시약·촉매·용매 2

HCID 887
Methanol
용매
HCID 3283Diethyl Ether용매

실험 절차

To a stirred solution of 3,4,5-trichloropyridazine (500 mg, 5.5 mmol) and DIPEA (1 mL) in propan-2-ol (5 mL) was added (R)-tert-butyl pyrrolidin-3-ylcarbamate (508 mg, 5.5 mmol) at ambient temperature. The solvent was removed and the residue was purified by column chromatography (petroleum ether/ethyl acetate=2/1, v/v) to afford the title desired product (500 mg, 55%). 1H NMR (300 MHz, CDCl3): 8.42 (s, 1H), 5.06 (br s, 1H), 4.36 (br s, 1H), 4.05-3.99 (m, 1H), 3.90-3.66 (m, 3H), 2.28-2.23 (m, 1H), 2.09-2.07 (m, 1H), 1.48 (s, 9H); LC-MS: m/z=333.1 [M+H]+ (R)-tert-butyl 1-(5-chloro-6-(2-methoxyethylamino)pyridazin-4-yl)pyrrolidin-3-ylcarbamate. A mixture of 100 mg of (R)-tert-butyl 1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-ylcarbamate and 2-methoxyethanamine (1 mL) was heated at 145° C. for 40 min in microwave. The mixture was concentrated and the crude was purified by silica gel chromatography (EA/PE=1/4, v/v) to give the title product (50 mg, 45%). LC-MS: m/z=372.2 [M+H]+. (R)-tert-butyl 1-(6-(2-methoxyethylamino)pyridazin-4-yl)pyrrolidin-3-ylcarbamate. To the mixture of (R)-tert-butyl 1-(5-chloro-6-(2-methoxyethylamino)pyridazin-4-yl)pyrrolidin-3-ylcarbamate (50 mg, 0.13 mmol) and ammonium formate (HCOONH4) (85 mg, 1.3 mmol) in MeOH (2 mL) was added 10% Pd/C (20 mg). The resulting mixture was refluxed for 2 hours. The reaction was allowed to cool to room temperature and filtered. The filtrate was concentrated, diluted with EA (20 mL) and washed with brine (10 mL*2). The combined organic layer was dried over Na2SO4 and concentrated. The residue was purified by pre-TLC (PE/EA=1/5, v/v) to give the product as oil (20 mg, 44%). 1H NMR (300 MHz, CDCl3): 8.02 (s, 1H), 5.46 (s, 1H), 5.10-5.08 (m, 1H), 4.91 (br s, 1H), 4.33-4.26 (m, 1H), 3.59-3.51 (m, 4H), 3.40-3.35 (m, 4H), 3.19-3.15 (m, 1H), 2.28-2.19 (m, 1H), 1.99-1.97 (m, 1H), 1.44 (s, 9H); LC-MS: m/z=338.2 [M+H]+. (R)-5-(3-aminopyrrolidin-1-yl)-N-(2-methoxyethyl)pyridazin-3-amine dihydrochloride. To solution of (R)-tert-butyl 1-(6-(2-methoxyethylamino)pyridazin-4-yl)pyrrolidin-3-ylcarbamate (198 mg, 0.59 mmol) in MeOH (3 mL) was added 7N HCl in ether (10 mL). The reaction was stirred at room temperature for 16 hours. The reaction was concentrated under reduced pressure to give the desired product as a light yellow solid (94.5 mg, 52%). 1H NMR (300 MHz, CD3OD): 8.14 (s, 1H), 6.12 (s, 1H), 4.15-3.54 (m, 9H), 3.40 (s, 3H), 2.57-2.52 (m, 1H), 2.32-2.30 (m, 1H); mass calcd. for C11H19N5O, 237.31, LC-MS: m/z=238.2 [M+H]+, tR=0.3 min; HPLC: 99% (214 nm), 95% (254 nm), tR=4.4 min. The compounds in Example 299 through Example 310 were prepared using methods analogous to those described in Example 298.

후처리

  1. concentrationThe reaction was concentrated under reduced pressure

출처 및 근거

ORD 기록
ord-a576320ed8fd4e8d9ecc56e9ff9f2656
출처 데이터셋
uspto-grants-2014_09
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08841287B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트